A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study

Abstract

Background-Tumor grade, size, resection potential, and extent of disease influence outcome in pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) but no risk stratification systems exist and the standard of care is poorly defined. This trial evaluated a risk stratification system developed from known prognostic factors in the context of risk-adapted therapy for young NRSTS patients. Treatment goals were to limit radiotherapy use in low-risk disease, decrease radiotherapy Spunt et al.

[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial

“…Following definitive therapy, CTX was continued for approximately 6 months (consolidation). Patients with synovial sarcoma ( n = 2) and embryonal sarcoma of the liver ( n = 2) were treated with doxorubicin and ifosfamide according to COG ARST0332 combined with surgery and radiation [ 19 ]. The treatment schemas for patients with osteosarcoma, synovial sarcoma, and embryonal sarcoma of the liver are shown in Fig.…”

Epithelioid Sarcoma—From Genetics to Clinical Practice

“…In children, ES is classified in the heterogeneous group of non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS). It accounts for about 5% of pediatric NRSTS cases [ 9 , 108 ]. Only a few data on clinical features and optimal treatment of pediatric patients are described in the literature.…”

“…The risk stratification system for young patients with NRSTS divided patients into three prognostic groups: low, intermediate, and high risk, with significantly different event-free survival (EFS) and OS (88.9%, 65%, 21.2% and 96.2%, 79.2%, 35.5%, respectively). Five factors were used in this system: Pediatric Oncology Group (POG) grade, tumor size, metastatic status, the extent of resection, and marginal status [ 108 ].…”

[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial 

“…Following de nitive therapy, CTX was continued for approximately 6 months (consolidation). Patients with synovial sarcoma (n=2) and embryonal sarcoma of the liver (n=2) were treated with doxorubicin and ifosfamide according to COG ARST0332 combined with surgery and radiation (19). The treatment schemas for patients with osteosarcoma, synovial sarcoma, and embryonal sarcoma of the liver are shown in Figure 2.…”